Bullish for Pharma: OTC NRT Access to Boost Tobacco Quit Rates

Experts are strongly advocating for making Nicotine Replacement Therapy (NRT) products, including 2mg and 4mg dosages, available over-the-counter (OTC) across all formats. This recommendation comes as India struggles with a tobacco quit success rate below 5%, highlighting the urgent need for accessible cessation aids.

Granting OTC access to NRT would significantly improve its availability and ease of purchase for millions of tobacco users in India. This could lead to a substantial increase in NRT adoption, directly impacting public health outcomes and creating a new growth avenue for pharmaceutical companies.

This development is highly positive for Indian pharmaceutical companies that manufacture or distribute NRT products. While specific companies are not named, major players with a presence in consumer healthcare or over-the-counter drugs could see a significant boost in sales. This includes companies like Cipla (CIPLA), Sun Pharma (SUNPHARMA), or Cadila Healthcare (CADILAHC) if they have NRT offerings.

Traders should monitor any regulatory announcements from the Indian government or health authorities regarding the reclassification of NRT products to OTC status. Also, keep an eye on pharmaceutical companies' product pipelines and marketing strategies for NRT, as well as any public health campaigns promoting tobacco cessation.

• •Experts back OTC access to NRT across all formats and dosages, including 2 mg and 4 mg.
• •India struggles with a Tobacco quit success rate under 5%.
• •Report highlights significant economic burden of tobacco use.
• •Risk flag: Slow regulatory approval process
• •Risk flag: Competition from alternative cessation methods